Novavax, Inc. Aktie News

Moderna, Inc. and Novavax, Inc. have transitioned from pandemic-era highs to focusing on cost reduction, pipeline development, and a path to breakeven by 2028. NVAX leverages partnerships with Sanofi and Pfizer, targeting ~$500m annual revenues by 2030, with a forward P/S of ~3x and P/E of ~7.5x. MRNA's growth depends on COVID/flu combo vaccine, intismeran cancer program, and RSV vaccine, but f...

Novavax signed a potentially lucrative deal with a pharmaceutical giant. However, the biotech's core business remains uncertain.

Novavax Inc. (NASDAQ:NVAX) shares are up 3.3% to trade at $8.27 at last glance, after the vaccine company  singed a licensing agreement -- worth up to $500 million, including a $30 million upfront payment -- with Pfizer (PFE) for use of its Matrix-M adjuvant for up to two disease areas.

Non-exclusive license allows for development by Pfizer to utilize Matrix-M ® for up to two disease areas with its products Provides Novavax with an upfront payment of $30 million with the potential for up to another $500 million in development and sales milestones. In addition to milestone payments, Novavax is eligible to receive high mid-single digit percentage royalties GAITHERSBURG, Md.

Novavax said on Tuesday it was entering into a licensing agreement with Pfizer to develop vaccine products for infectious diseases.

Novavax, Inc. (NVAX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

GAITHERSBURG, Md., Jan. 7, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the 44th Annual J.P.

Novavax faces plenty of uncertainty related to a deal it signed with a larger company. The biotech's pipeline doesn't look that exciting either.